Unraveling the Pulmonary Fate of Fluticasone and Friends: Meeting the Physiologic and Pharmacokinetic Challenges
Exploring the role of DPI (Dry powder inhaler) in drug development and the inhalation process and pharmacokinetics of fluticasone propionate.
Elucidating Molecular- and Particle-Level Changes during the Annealing of a Micronized Crystalline Drug
Nanopharm explores annealing in micronized DPIs for drug development. Focus on molecular changes and SFE in Dry Powder Inhaler formulations.
Challenging the Bioequivalence Hurdles for OINDPs: Achieving Q3 Structural Equivalence
Explore challenges in OINDP drug development, focusing on achieving bioequivalence in generic nasal formulations.
Characterizing Nasal Suspensions for Regulatory and Scientific Purposes
Explore Nanopharm’s in-depth research on particle size and its role in in vitro bioequivalence for nasal drug delivery. Discover how particle sizing impacts regulatory compliance and drug efficacy.
Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers
Explore Nanopharm’s in-depth in vitro study on dry powder inhalers (DPIs). Learn how Computational Fluid Dynamics and Particle Size Distribution contribute to device performance and comparability.
The Influence of Secondary Processing on the Structural Relaxation Dynamics of Fluticasone Propionate
Nanopharm explores structural dynamics of Fluticasone Propionate in DPIs. Focus on APSD in Dry Powder Inhaler formulations.
Advanced microscopy techniques to assess solid-state properties of inhalation medicines
Unveil Nanopharm’s expertise in advanced microscopy for OINDP. Explore solid-state analysis and its impact on inhalation medicines, including dry powder inhalers.
